UBS Group’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.9M | Sell |
596,554
-1,441
| -0.2% | -$40.9K | ﹤0.01% | 2000 |
|
|
2025
Q1 | $17.7M | Buy |
597,995
+392,089
| +190% | +$11.6M | ﹤0.01% | 1891 |
|
|
2024
Q4 | $5.99M | Buy |
205,906
+28,030
| +16% | +$815K | ﹤0.01% | 2809 |
|
|
2024
Q3 | $8.17M | Buy |
177,876
+73,493
| +70% | +$3.38M | ﹤0.01% | 1840 |
|
|
2024
Q2 | $4.26M | Sell |
104,383
-91,063
| -47% | -$3.72M | ﹤0.01% | 2254 |
|
|
2024
Q1 | $4.99M | Buy |
195,446
+1,095
| +0.6% | +$27.9K | ﹤0.01% | 2195 |
|
|
2023
Q4 | $1.76M | Buy |
194,351
+78,387
| +68% | +$709K | ﹤0.01% | 2974 |
|
|
2023
Q3 | $740K | Sell |
115,964
-67,102
| -37% | -$428K | ﹤0.01% | 3334 |
|
|
2023
Q2 | $2.03M | Buy |
183,066
+101,832
| +125% | +$1.13M | ﹤0.01% | 2681 |
|
|
2023
Q1 | $1.25M | Sell |
81,234
-83,754
| -51% | -$1.29M | ﹤0.01% | 2999 |
|
|
2022
Q4 | $3.66M | Buy |
164,988
+137,167
| +493% | +$3.04M | ﹤0.01% | 2081 |
|
|
2022
Q3 | $455K | Sell |
27,821
-13,258
| -32% | -$217K | ﹤0.01% | 3445 |
|
|
2022
Q2 | $597K | Sell |
41,079
-49,787
| -55% | -$724K | ﹤0.01% | 3230 |
|
|
2022
Q1 | $1.68M | Buy |
90,866
+8,638
| +11% | +$160K | ﹤0.01% | 2802 |
|
|
2021
Q4 | $1.96M | Buy |
82,228
+44,542
| +118% | +$1.06M | ﹤0.01% | 2893 |
|
|
2021
Q3 | $928K | Buy |
37,686
+33,866
| +887% | +$834K | ﹤0.01% | 3307 |
|
|
2021
Q2 | $94K | Sell |
3,820
-27,056
| -88% | -$666K | ﹤0.01% | 4891 |
|
|
2021
Q1 | $673K | Buy |
30,876
+28,979
| +1,528% | +$632K | ﹤0.01% | 3700 |
|
|
2020
Q4 | $49K | Buy |
+1,897
| New | +$49K | ﹤0.01% | 5210 |
|